In Keun Choi
Overview
Explore the profile of In Keun Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong S, Choi I, Jeong W, Lee S, Sung H, Hong S, et al.
J Ethnopharmacol
. 2017 Mar;
202:1-11.
PMID: 28284790
Ethnopharmacological Relevance: Ulmus davidiana Nakai (UDN) is frequently used in the treatment of cancer in traditional oriental medicine. Although several reports indicate that UDN has inhibitory effects in some cancers,...
2.
Lee C, Choi I, Kim J, Park D, Kim J, Park S
Ann Surg Treat Res
. 2017 Jan;
92(1):23-27.
PMID: 28090502
Purpose: The purpose of this study is to suggest a treatment strategy for stage IV gastric cancer by investigating the behavioral difference between initially and recurrent metastatic disease. Methods: We...
3.
Sung H, Lee S, Choi I, Park Y, Choi C, Kim H, et al.
Acta Haematol
. 2015 Apr;
134(1):59-68.
PMID: 25871321
Aim: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose. This study aimed to find...
4.
Choi I, Hyun J, Kim S, Jung S, Koo J, Kim J, et al.
Oncol Res Treat
. 2014 Jun;
37(6):310-4.
PMID: 24903761
Background: Socioeconomic inequalities are known to influence the survival of cancer patients due to differences in treatment modalities and disease extent at diagnosis. However, there are few studies regarding the...
5.
Lee J, Kang S, Kim S, Kang S, Choi I, Park Y, et al.
Cancer Res Treat
. 2014 May;
46(2):172-7.
PMID: 24851109
Purpose: There is no established standard second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who failed gemcitabine and cisplatin (GC) chemotherapy. This study was conducted in order...
6.
Park J, Lee S, Kim H, Kang S, Ko Y, Kim S, et al.
Cancer Chemother Pharmacol
. 2013 Feb;
71(4):1033-9.
PMID: 23370665
Purpose: Although cisplatin-based chemotherapy is the standard of care for advanced transitional cell carcinoma, tolerability is a challenging issue in unfit patients. This study was conducted to evaluate the efficacy,...
7.
Park S, Choi I, Seo H, Sung H, Park K, Oh S, et al.
Oncol Lett
. 2012 Sep;
1(1):51-55.
PMID: 22966255
Recently, third-line chemotherapy for advanced non-small cell lung cancer (NSCLC) was accepted as a reasonable therapeutic option in patients with a favorable performance status. In practice, however, palliative chemotherapy has...
8.
Choi I, Sung H, Lee J, Kim J, Seo J
Cancer Chemother Pharmacol
. 2012 Aug;
70(4):555-8.
PMID: 22871922
Purpose: Several reports have shown a better prognosis in gastric cancer patients who are positive for Helicobacter pylori (HP) infection compared with negative cases. However, there are currently no studies...
9.
Joo Kang E, Choi Y, Kim J, Kim S, Park K, Choi I, et al.
Asia Pac J Clin Oncol
. 2010 Dec;
6(4):286-91.
PMID: 21114778
Aim: There is no further treatment option for metastatic colon patients who are refractory to standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes...
10.
Choi I, Kim Y, Kim J, Seo J
Acta Oncol
. 2010 Jun;
49(6):861-4.
PMID: 20553098
No abstract available.